文献速递骨质疏松与代谢性骨病

生物类似药与参照地舒单抗治疗绝经后骨质疏松疗效比较:系统综述与荟萃分析

Comparative efficacy of biosimilar denosumab and reference denosumab in treatment of postmenopausal osteoporosis: a systematic review and meta-analysis.
PubMed 文献 · Osteoporos Int · 2026-07-29

该荟萃分析纳入7项随机对照试验(n=2251),比较参照地舒单抗与生物类似药地舒单抗治疗绝经后骨质疏松的疗效。两组腰椎骨密度(LS BMD)相当,参照地舒单抗在全髋骨密度(TH BMD)上略有优势;骨转换标志物、骨折、治疗中出现的不良事件(TAEs)及抗药抗体(ADA)阳性率均无显著差异。生物类似药地舒单抗在疗效、安全性和免疫原性方面与参照药相当。

要点

  • 生物类似药与参照地舒单抗的腰椎骨密度疗效相当(MD=0.02)。
  • 参照地舒单抗在全髋骨密度上略有优势(MD=0.24,95%CI 0.01–0.47,P=0.04)。
  • 骨转换标志物、骨折、TAEs及ADA阳性率两组无显著差异。

核心结论

  • 生物类似药地舒单抗在疗效、安全性和免疫原性方面与参照地舒单抗相当。
  • 仍需长期使用及不同人群的研究来监测生物类似药地舒单抗的疗效与安全性。

研究设计与样本

  • 遵循PRISMA指南,系统检索PubMed、Google Scholar和Cochrane Library。
  • 纳入7项比较参照地舒单抗与生物类似药地舒单抗的随机对照试验(RCTs),共2251例≥45岁确诊骨质疏松的绝经后女性。
  • 主要结局为腰椎骨密度(LS BMD),采用RevMan 5.4.1随机效应模型分析。

主要发现

  • 两组腰椎骨密度(LS BMD)相当(MD=0.02;95% CI -0.30, 0.34;P=0.92)。
  • 参照地舒单抗组全髋骨密度(TH BMD)显著改善(MD=0.24;95% CI 0.01, 0.47;P=0.04)。
  • 骨转换标志物、骨折、治疗中出现的不良事件(TAEs)及抗药抗体(ADA)阳性率均无显著差异。

临床怎么用

  • 生物类似药地舒单抗可作为参照地舒单抗的有效、安全且成本效益更优的替代选择。
  • 临床决策时需注意参照地舒单抗在全髋骨密度上略有优势,但差异较小。

局限性

  • 长期使用及不同人群的疗效与安全性仍需进一步研究监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This meta-analysis addressed limited comparative evidence between reference and biosimilar denosumab. Across seven RCTs, both showed equivalent lumbar spine BMD, with a small hip BMD advantage for reference denosumab, supporting biosimilars as effective, safe, and cost-efficient alternatives. BACKGROUND: Osteoporosis is the most prevalent metabolic bone disorder in postmenopausal women. Addressing the gap in literature, our study compares efficacy of reference and biosimilar denosumab in treatment of postmenopausal osteoporosis. METHODOLOGY: Following PRISMA guidelines, we systematically searched PubMed, Google Scholar, and Cochrane Library. Only randomized control trials (RCTs) comparing original denosumab with biosimilar denosumab conducted in postmenopausal women diagnosed with osteoporosis aged ≥ 45 years were included with Lumbar Spine-Bone Mineral Density (LS BMD) as primary outcome. Analysis was conducted using a random effects model on RevMan 5.4.1. RESULTS: Seven RCTs (n = 2251) were included. Both groups showed comparable LS BMD (MD = 0.02; 95% CI -0.30, 0.34; P = 0.92), while Total Hip BMD (TH BMD) was significantly improved with reference denosumab use (MD = 0.24; 95% CI 0.01, 0.47; P = 0.04). Bone turnover markers, fractures, TAEs, and ADA positivity showed no significant differences. CONCLUSION: Biosimilar denosumab demonstrates comparable efficacy, safety and immunogenicity to reference denosumab. Although, studies are necessary to monitor the efficacy and safety of biosimilar denosumab in long term use and different populations.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Zainab S, Zaheer L, Sheikh AR, et al. Comparative efficacy of biosimilar denosumab and reference denosumab in treatment of postmenopausal osteoporosis: a systematic review and meta-analysis. Osteoporos Int. 2026. PMID: 42521873. doi:10.1007/s00198-026-08159-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。